Literature DB >> 863812

Glucose-induced decrease in glucagon and pinephrine responses to exercise in man.

H Galbo, N J Christensen, J J Holst.   

Abstract

Seven men ran at 60% of individual maximal oxygen uptake to exhaustion during beta-adrenergic blockade with propranolol or without drugs. After propranolol administration the increases during exercise in plasma glucagon and epinephrine concentrations as well as the decrease in plasma glucose concentrations were faster than in control experiments. When euglycemia was maintained by glucose infusion during beta-adrenergic blockade, glucagon and epinephrine responses to exercise, although not abolished, were markedly reduced. The diminution of the exercise-induced decline in glucose concentrations correlated significantly with the diminution of the glucagon as well as the epinephrine responses. Thus decreased glucose concentrations may significantly enhance the secretion of glucagon and epinephrine during prolonged exercise in man. Since the diminution of the glucagon response produced by glucose infusion was not accompanied by significant alterations in the levels of nonesterified fatty acid (NEFA) and glycerol, increased glucagon secretion does not seem to be a major determinant of lipolysis during exercise in man. During glucose infusion, glycogen utilization rates in muscle (n = 4) tended to decrease, whereas carbohydrate combustion rate and concentrations of norepinephrine, insulin, alanine, and lactate were unchanged.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 863812     DOI: 10.1152/jappl.1977.42.4.525

Source DB:  PubMed          Journal:  J Appl Physiol Respir Environ Exerc Physiol        ISSN: 0161-7567


  24 in total

1.  Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man.

Authors:  N J Christensen; J Trap-Jensen; T L Svendsen; S Rasmussen; P E Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

Review 2.  Catecholamines and diabetes mellitus.

Authors:  N J Christensen
Journal:  Diabetologia       Date:  1979-04       Impact factor: 10.122

3.  Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.

Authors:  H J Kornerup; E B Pedersen; N J Christensen; A Pedersen; G Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

Review 4.  Exercise and the immune response.

Authors:  D Keast; K Cameron; A R Morton
Journal:  Sports Med       Date:  1988-04       Impact factor: 11.136

5.  Effect of calcium channel blockade and beta-adrenoceptor blockade on short graded and single-level endurance exercises in normal men.

Authors:  L Vanhees; R Fagard; A Amery
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1988

6.  Impact of elevated ambient temperatures on the acute immune response to intensive endurance exercise.

Authors:  A M Niess; E Fehrenbach; R Lehmann; L Opavsky; M Jesse; H Northoff; H-H Dickhuth
Journal:  Eur J Appl Physiol       Date:  2003-03-25       Impact factor: 3.078

7.  Strenuous exercise decreases motility and cross-sectional area of human gastric antrum. A study using ultrasound.

Authors:  B P Brown; M A Ketelaar; K Schulze-Delrieu; M M Abu-Yousef; C K Brown
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

8.  [Behavior of free catecholamines in blood and urine of ambulance men and physicians during quick responses].

Authors:  M Lehmann; V Dörges; G Huber; G Zöllner; U Spöri; J Keul
Journal:  Int Arch Occup Environ Health       Date:  1983       Impact factor: 3.015

9.  [Plasma catecholamines, metabolic substrates, aerobic and anaerobic capacity during graduated treadmill and bicycle ergometer exercise (author's transl)].

Authors:  M Lehmann; J Keul; K Wybitul
Journal:  Klin Wochenschr       Date:  1981-06-01

10.  Exercise-induced hyperkalaemia: effects of beta-adrenoceptor blocker vs diuretic.

Authors:  J Cleroux; M Peterson; F H Leenen
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.